Cancer multitarget pharmacology in prostate tumors: Tyrosine kinase inhibitors and beyond

Current Medicinal Chemistry

Volumn 18, Issue 19, 2011, Pages 2827-2835

  Bologna, M ^a   Vicentini, C ^b   Muzi, P ^a   Pace, G ^b   Angelucci, A ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cancer therapy; Chemotherapy; Combination therapy; Prostate cancer; Tyrosine kinase inhibitors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; DASATINIB; DOCETAXEL; DUTASTERIDE; ERLOTINIB; ESTRAMUSTINE; ETOPOSIDE; FINASTERIDE; FISETIN; GEFITINIB; GONADORELIN ANTAGONIST; IMATINIB; ISOLIQUIRITIGENIN; LAPATINIB; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; ZIBOTENTAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; DATA ANALYSIS; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATION; POLYPHARMACY; PROSTATE TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 79960008213     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796150487     Document Type: Article

References (70)

1. Goodman, L. S.; Wintrobe, M. M.; Dameshek, W.; Goodman, M. J.; Gilman, A.; McLennan, M. T. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA, 1984, 251(17), 2255-2261 (Pubitemid 14135443)
2. Gilman, A. The initial clinical trial of nitrogen mustard. Am J Surg, 1963, 105, 574-578.
3. Chabner, B. A.; Roberts, T. G. Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer, 2005, 5(1), 65-72.
4. Hirsch, J., An anniversary for cancer chemotherapy. JAMA, 2006. 296(12): p. 1518-20. (Pubitemid 44465516)
5. Chalmers, A. J. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull, 2009, 89:23-40.
6. Ma, Z., et al., Global tuberculosis drug development pipeline: the need and the reality. Lancet, 2010. 375(9731): p. 2100-9.
7. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 2009, 9(1), 28-39.
8. Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. Nat Rev Cancer, 2009, 9(1), 57-63.
9. Ulrich, C. M.; Bigler, J.; Potter, J. D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer, 2006, 6(2), 130-140. (Pubitemid 43361545)
10. Nishio, Y; Yamada, Y; Kokubo, H; Nakamura, K; Aoki, S; Taki, T; Honda, N; Nakagawa, A; Saga, S; Hara, K. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology, 2006, 68(1), 110-115 (Pubitemid 44037732)
11. Imai, K; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer, 2006, 6(9), 714-727. (Pubitemid 44286003)
12. Angelucci, A; Gravina, G. L.; Rucci, N.; Millimaggi, D.; Festuccia, C.; Muzi, P.; Teti, A.; Vicentini, C.; Bologna, M. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer, 2006, 13(1), 197-210.
13. Angelucci, A. Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. Curr Cancer Drug Targets, 2009, 9(1), 1-18.
14. Pezaro, C.; Rosenthal, M. A.; Gurney, H.; Davis, I. D.; Underhill, C,; Boyer, M. J.; Kotasek, D.; Solomon, B.; Toner, G. C. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castrationresistant prostate cancer. Am J Clin Oncol, 2009, 32(4), 338-341.
15. Sridhar, S. S.; Hotte, S. J.; Chin, J. L.; Hudes, G. R.; Gregg, R.; Trachtenberg, J.; Wang, L.; Tran-Thanh, D.; Pham, N. A.; Tsao, M. S.; Hedley, D.; Dancey, J. E.; Moore, M. J. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. Am J Clin Oncol, 2010, 33(6), 609-13.
16. Melnyk, O.; Zimmerman, M.; Kim, K. J.; Shuman, M. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol, 1999, 161(3), 960-3. (Pubitemid 29422416)
17. Ryan, C. J.; Lin, A. M.; Small, E. J. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol, 2006, 24(3), 250-3.
18. George, D.; Liu, G.; Wilding, G. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer-preliminary results. J Clin Oncol, 2008, 26(Suppl), 5131a.
19. Chi, K. N.; Ellard, S. L.; Hotte, S. J.; Czaykowski, P,; Moore, M.; Ruether, J. D.; Schell, A. J.; Taylor, S.; Hansen, C.; Gauthier, I.; Walsh, W.; Seymour, L. A phase II study of sorafenib in patients with chemo-naive castrationresistant prostate cancer. Ann Oncol, 2008, 19(4), 746-751. (Pubitemid 351461047)
20. Angelucci, A.; Schenone, S.; Gravina, G. L.; Muzi, P.; Festuccia, C.; Vicentini, C.; Botta, M.; Bologna, M. Pyrazolo[3, 4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer, 2006, 42(16), 2838-45. (Pubitemid 44584669)
21. Yang, J. C.; Bai, L.; Yap, S.; Gao, A. C.; Kung, H. J.; Evans, C. P. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther, 2010, 9(6), 1629-1637.
22. Saito, Y. D.; Jensen, A. R.; Salgia, R.; Posadas, E. M. Fyn: A novel molecular target in cancer. Cancer, 2010, 116(7), 1629-1637.
23. Yu, E. Y.; Wilding, G.; Posadas, E.; Gross, M.; Culine, S.; Massard, C.; Morris, M. J.; Hudes, G.; Calabrò, F.; Cheng, S.; Trudel, G. C.; Paliwal, P.; Sternberg, C. N. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res, 2009, 15(23), 7421-7428.
24. Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schönenberger A, Knuth A, Borner M. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie. 2007 Jul; 30(7), 355-60. (Pubitemid 47013371)
25. Boccardo F, Rubagotti A, Conti G, Battaglia M, Cruciani G, Manganelli A, Ricci S, Lapini A. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology. 2008;74(3-4), 223-8. Epub 2008 Aug. 20.
26. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006 May 1;106(9), 1917-24 (Pubitemid 43673206)
27. National Institute of Mental Health; University of Virginia. Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00483561 NLM Identifier: NCT00483561.
28. ™ in Locally Advanced Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00319787 NLM Identifier: NCT00319787.
29. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul. 27;7:142.
30. National Institute of Mental Health; University of Virginia. Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials. gov/show/NCT00953576 NLM Identifier: NCT00953576.
31. Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15;100(10), 2125-31. (Pubitemid 38580330)
32. Lipton A, Campbell-Baird C, Harvey H, Kim C, Demers L, Costa L. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. Am J Clin Oncol. 2010 Feb; 33(1), 75-8.
33. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct. 1;13(19), 5816-24. (Pubitemid 47583906)
34. National Institute of Mental Health; University of Virginia. Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgenindependent Prostate Cancer (AIPC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00424385 NLM Identifier: NCT00424385.
35. National Institute of Mental Health; University of Virginia. Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT01260688 NLM Identifier: NCT01260688.
36. National Institute of Mental Health; University of Virginia. Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00744497 NLM Identifier: NCT00744497.
37. National Institute of Mental Health; University of Virginia. Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/ NCT00439270 NLM Identifier: NCT00439270.
38. National Institute of Mental Health; University of Virginia. 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/ NCT00121264 NLM Identifier: NCT00121264.
39. National Institute of Mental Health; University of Virginia. Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/ NCT00203424 NLM Identifier: NCT00203424.
40. National Institute of Mental Health; University of Virginia. Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00098592 NLM Identifier: NCT00098592.
41. C11-National Institute of Mental Health; University of Virginia. Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/ NCT00500110 NLM Identifier: NCT00500110.
42. C12-National Institute of Mental Health; University of Virginia. Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Jan 18]. Available from: http://clinicaltrials.gov/show/NCT00452387 NLM Identifier: NCT00452387.
43. Bologna, M.; Muzi, P.; Biordi, L.; Festuccia, C.; Vicentini, C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology, 1995, 45(2), 282-290.
44. Festuccia, C.; Gravina, G. L.; Muzi, P.; Pomante, R.; Angelucci, A.; Vicentini, C.; Bologna, M. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. J Urol, 2008, 180(1), 367-372.
45. Vicentini, C.; Festuccia, C.; Gravina, G. L.; Angelucci, A.; Marronaro, A.; Bologna, M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J. Canc. Res. Clin. Oncol., 2003, 129, 165-174. (Pubitemid 36583697)
46. Gravina, G. L.; Festuccia, C.; Angelucci, A.; Poletti, A.; Capuano, D.; Vicentini, C.; Motta, M.; Bologna, M. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol, 2004, 25(1), 97-104.
47. Festuccia, C.; Gravina, G. L.; Angelucci, A.; Millimaggi, D.; Muzi, P.; Vicentini, C.; Bologna, M. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer, 2005, 115(4), 630-640. (Pubitemid 40656723)
48. Festuccia, C.; Muzi, P.; Millimaggi, D.; Biordi, L.; Gravina, G. L.; Speca, S.; Angelucci, A.; Dolo, V.; Vicentini, C.; Bologna, M. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer, 2005, 12(4), 983-998. (Pubitemid 41815791)
49. Gravina, G. L.; Festuccia, C.; Galatioto, G. P.; Muzi, P.; Angelucci, A.; Ronchi, P.; Costa, A. M.; Bologna, M.; Vicentini, C. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology, 2007, 70(4), 728-733. (Pubitemid 350030219)
50. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 4(11), 682-90.
51. Knight, Z. A.; Lin, H.; Shokat K. M. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer, 2010, 10(2), 130-137.
52. Huggins, C.; Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 2002, 168(1), 9-12.
53. Isbarn, H.; Boccon-Gibod, L.; Carroll, P. R.; Montorsi, F.; Schulman, C.; Smith, M. R.; Sternberg, C. N.; Studer, U. E. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009 Jan; 55(1), 62-75.
54. Akaza, H.; Hinotsu, S.; Usami, M.; Arai, Y.; Kanetake, H.; Naito, S.; Hirao, Y. Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009 Aug; 115(15), 3437-45
55. Wang, Y.; Gupta, S.; Hua, V.; Ramos-Garcia, R.; Shevrin, D.; Jovanovic, B. D.; Nelson, J. B.; Wang, Z. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate 2010 Feb. 1;70(2), 147-54
56. Sissung, T. M., Thordardottir, S.; Gardner, E. R.; Figg, W. D. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. Anticancer Agents Med Chem, 2009, 9(10), p. 1058-69.
57. Hurtado, A., Pinos, T.; Barbosa-Desongles, A.; Lopez-Aviles, S.; Barquinero, J.; Petriz, J.; Santamaria-Martinez, A.; Morote, J.; de Torres, I.; Bellmunt, J.; Reventos, J.; Munell, F. Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a nongenomic mechanism in prostate carcinoma cells. Cell Oncol 2008;30(4), 349-65. (Pubitemid 352032910)
58. Bonkhoff, H. and R. Berges, The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol, 2009. 55(3);533-42.
59. Boccon-Gibod, L.; Hammerer, P.; Madersbacher, S.; Mottet, N.; Prayer-Galetti, T.; Tunn, U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007 Oct; 100(4), 738-43 (Pubitemid 47360177)
60. Shaw, G. and D. M. Prowse, Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int, 2008. 8, 3.
61. Mimeault, M.; Jouy, N.; Depreux, P.; Henichart, J. P. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Prostate, 2005, 62(2), 187-99. (Pubitemid 40096783)
62. Slovin, S. F.; Kelly, W. K.; Wilton, A.; Kattan, M.; Myskowski, P.; Mendelsohn, J.; Scher, H. I. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 2009, 7(3), E77-82.
63. Sinha, A. A.; Quast, B. J.; Wilson, M. J.; Fernandes, E. T.; Reddy, P. K.; Ewing, S. L.; Sloane, B. F.; Gleason, D. F. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate, 2001, 48(4), 274-84. (Pubitemid 32816553)
64. Chien, C. S.; Shen, K. H.; Huang, J. S.; Ko S. C.; Shih, Y. W. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem, 2010, 333(1-2), 169-180.
65. Shen, K. H.; Hung, S. H.; Yin, L. T.; Huang, C. S.; Chao, C. H.; Liu, C. L.; Shih, Y. W. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem, 2010, 333(1-2), 279-291.
66. Lee, Y. M.; Lim do, Y.; Choi, H. J.; Jung, J. I.; Chung, W. Y.; Park, J. H. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. J Med Food, 2009, 12(1), 8-14.
67. Kwon, G. T.; Cho, H. J.; Chung, W. Y.; Park, K. K.; Moon, A.; Park, J. H. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem, 2009, 20(9), 663-676.
68. Morgan, T. M.; Koreckij, T. D.; Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Ta rgets, 2009, 9(2), 237-249.
69. Ning, Y. M.; Figg, W. D.; Dahut, W. L. Reversal of docetaxel resistance with bevacizumab and thalidomide. Clin Genitourin Cancer, 2009, 7(2), E37-38.
70. Ortholan, C.; Durivault, J.; Hannoun-Levi, J. M.; Guyot, M.; Bourcier, C.; Ambrosetti, D.; Safe, S.; Pagès, G. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer, 2010, 46(16), 3022-3036.